免疫肿瘤学要点:概述

Journal of the advanced practitioner in oncology Pub Date : 2019-03-01 DOI:10.6004/jadpro.2019.10.2.9

Brianna W. Hoffner

{"title":"免疫肿瘤学要点:概述","authors":"Brianna W. Hoffner","doi":"10.6004/jadpro.2019.10.2.9","DOIUrl":null,"url":null,"abstract":"© 2019 HarborsideTM We are honored to share with you this supplement entitled ImmunoOncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events. Immunotherapy with immune checkpoint inhibitors (ICIs) has remarkably revolutionized cancer care, improving outcomes for many patients with diverse tumor types. The awarding of the 2018 Nobel Prize in Medicine to two of the scientists involved with ICI development, James P. Allison and Tasuku Honjo, is a testament to this fact. The impact of ICIs is likely to continue to expand, as these therapies are used in an ever-growing","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"7 - 8"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immuno-Oncology Essentials: An Overview\",\"authors\":\"Brianna W. Hoffner\",\"doi\":\"10.6004/jadpro.2019.10.2.9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"© 2019 HarborsideTM We are honored to share with you this supplement entitled ImmunoOncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events. Immunotherapy with immune checkpoint inhibitors (ICIs) has remarkably revolutionized cancer care, improving outcomes for many patients with diverse tumor types. The awarding of the 2018 Nobel Prize in Medicine to two of the scientists involved with ICI development, James P. Allison and Tasuku Honjo, is a testament to this fact. The impact of ICIs is likely to continue to expand, as these therapies are used in an ever-growing\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"10 1\",\"pages\":\"7 - 8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2019.10.2.9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.6004/jadpro.2019.10.2.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

©2019 harborsiddetm我们很荣幸与您分享这份题为《免疫肿瘤治疗要点:免疫相关不良事件的主动管理》的增刊。免疫检查点抑制剂(ICIs)的免疫治疗已经显著地改变了癌症治疗，改善了许多不同肿瘤类型患者的预后。2018年诺贝尔医学奖授予参与ICI开发的两位科学家詹姆斯·p·艾利森(James P. Allison)和本庶寿(Tasuku Honjo)就是这一事实的证明。ici的影响可能会继续扩大，因为这些疗法在越来越多的疾病中的应用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immuno-Oncology Essentials: An Overview

© 2019 HarborsideTM We are honored to share with you this supplement entitled ImmunoOncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events. Immunotherapy with immune checkpoint inhibitors (ICIs) has remarkably revolutionized cancer care, improving outcomes for many patients with diverse tumor types. The awarding of the 2018 Nobel Prize in Medicine to two of the scientists involved with ICI development, James P. Allison and Tasuku Honjo, is a testament to this fact. The impact of ICIs is likely to continue to expand, as these therapies are used in an ever-growing

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the advanced practitioner in oncology

自引率

0.00%

发文量